Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427826 | 0.89 | SLC1A2 (0.58) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL17756064 | 0.89 | SLC1A2 (0.58) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL17756096 | 0.79 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL2177343 | 0.79 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL9507401 | 0.76 | SLC1A2 (0.38) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL1297246 | 0.75 | BTK (0.45) | MEN1BLMKMT2ABTK | |
| SCHEMBL11888996 | 0.74 | SLC1A2 (0.72) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL27190337 | 0.73 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL5746785 | 0.73 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL9511045 | 0.73 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986384-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2012-02-22 | — | — | EP | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |